Skip to main content
Erschienen in: Die Kardiologie 3/2020

23.01.2020 | Zytokine | Übersichten

Von der Haut zum Gefäßsystem – Psoriasis und das kardiovaskuläre Risiko

verfasst von: Dr. med. Johannes Wild, Joanna Wegner, Dr. med. Susanne Karbach

Erschienen in: Die Kardiologie | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Psoriasis ist eine Interleukin-17A (IL-17A) mediierte Hauterkrankung, die mit einem erhöhten kardiovaskulären Risiko einhergeht. Sie stellt eine der häufigsten chronischen Hauterkrankungen in den europäischen Industrienationen dar. Lange Zeit wurde die kardiovaskuläre Komorbidität der Psoriasis auf ein vermehrt vorliegendes klassisches kardiovaskuläres Risikoprofil von Psoriasispatienten zurückgeführt wie Rauchen oder Adipositas. Mittlerweile weiß man jedoch, dass die schwere Psoriasis an sich ein neuer eigenständiger kardiovaskulärer Risikofaktor ist. Da das Zytokin IL-17A sowohl zu Hautinflammation als auch zu vaskulärer Inflammation führen kann, stellt es ein naheliegendes Bindeglied zwischen der Psoriasis und der kardiovaskulären Erkrankung dar. Eine kardiologische Mitbetreuung von Patienten mit schwerer Psoriasis scheint neben der dermatologischen Versorgung essenziell.
Literatur
1.
Zurück zum Zitat Brenner S, Miller JH (2001) Encyclopedia of genetics. Elsevier Science Inc, 1581–1582 Brenner S, Miller JH (2001) Encyclopedia of genetics. Elsevier Science Inc, 1581–1582
2.
Zurück zum Zitat McDonald CJ, Calabresi P (1973) Thromboembolic disorders associated with psoriasis. Arch Dermatol 107:918PubMedCrossRef McDonald CJ, Calabresi P (1973) Thromboembolic disorders associated with psoriasis. Arch Dermatol 107:918PubMedCrossRef
3.
Zurück zum Zitat Spah F (2008) Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 159(Suppl 2):10–17PubMedCrossRef Spah F (2008) Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 159(Suppl 2):10–17PubMedCrossRef
4.
Zurück zum Zitat Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRef Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRef
5.
Zurück zum Zitat Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, Kaufmann R, Vogl TJ, Boehncke WH (2007) Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156:271–276PubMedCrossRef Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, Kaufmann R, Vogl TJ, Boehncke WH (2007) Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156:271–276PubMedCrossRef
6.
Zurück zum Zitat Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J 31:1000–1006PubMedCrossRef Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J 31:1000–1006PubMedCrossRef
7.
Zurück zum Zitat Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, on behalf of the Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133:377–385PubMedCrossRef Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, on behalf of the Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133:377–385PubMedCrossRef
9.
Zurück zum Zitat Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34:J314–321PubMedCrossRef Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34:J314–321PubMedCrossRef
10.
Zurück zum Zitat Di Cesare A, Di Meglio P, Nestle FO (2009) The il-23/th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129:1339–1350PubMedCrossRef Di Cesare A, Di Meglio P, Nestle FO (2009) The il-23/th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129:1339–1350PubMedCrossRef
11.
12.
Zurück zum Zitat Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tschachler E (2010) Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol 6:704–714PubMedCrossRef Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tschachler E (2010) Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol 6:704–714PubMedCrossRef
13.
14.
Zurück zum Zitat Onishi RM, Gaffen SL (2010) Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease. Immunology 129:311–321PubMedPubMedCentralCrossRef Onishi RM, Gaffen SL (2010) Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease. Immunology 129:311–321PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263–271PubMedCrossRef Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263–271PubMedCrossRef
16.
Zurück zum Zitat van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the il–23/il–17 axis. J Immunol 182:5836–5845PubMedCrossRef van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the il–23/il–17 axis. J Immunol 182:5836–5845PubMedCrossRef
17.
Zurück zum Zitat Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, Harle P, Hoffstadt B, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Rzany B, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T (2018) S3 guideline for the treatment of psoriasis vulgaris, update - short version part 1—systemic treatment. J Dtsch Dermatol Ges 16:645–669PubMed Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, Harle P, Hoffstadt B, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Rzany B, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T (2018) S3 guideline for the treatment of psoriasis vulgaris, update - short version part 1—systemic treatment. J Dtsch Dermatol Ges 16:645–669PubMed
18.
Zurück zum Zitat Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, Harle P, Hoffstadt B, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Rzany B, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T (2018) S3 guideline for the treatment of psoriasis vulgaris, update—short version part 2—special patient populations and treatment situations. J Dtsch Dermatol Ges 16:806–813PubMed Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, Harle P, Hoffstadt B, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Rzany B, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T (2018) S3 guideline for the treatment of psoriasis vulgaris, update—short version part 2—special patient populations and treatment situations. J Dtsch Dermatol Ges 16:806–813PubMed
19.
Zurück zum Zitat Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12:204–212PubMedCrossRef Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12:204–212PubMedCrossRef
20.
Zurück zum Zitat Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM (2011) Inflammation, immunity, and hypertension. Hypertension 57:132–140CrossRefPubMed Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM (2011) Inflammation, immunity, and hypertension. Hypertension 57:132–140CrossRefPubMed
21.
Zurück zum Zitat Wenzel P, Knorr M, Kossmann S, Stratmann J, Hausding M, Schuhmacher S, Karbach SH, Schwenk M, Yogev N, Schulz E, Oelze M, Grabbe S, Jonuleit H, Becker C, Daiber A, Waisman A, Munzel T (2011) Lysozyme m‑positive monocytes mediate angiotensin ii-induced arterial hypertension and vascular dysfunction. Circulation 124:1370–1381PubMedCrossRef Wenzel P, Knorr M, Kossmann S, Stratmann J, Hausding M, Schuhmacher S, Karbach SH, Schwenk M, Yogev N, Schulz E, Oelze M, Grabbe S, Jonuleit H, Becker C, Daiber A, Waisman A, Munzel T (2011) Lysozyme m‑positive monocytes mediate angiotensin ii-induced arterial hypertension and vascular dysfunction. Circulation 124:1370–1381PubMedCrossRef
22.
Zurück zum Zitat Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM (2006) Nadph oxidases in cardiovascular health and disease. Antioxidants & Redox Signaling 8:691–728CrossRef Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM (2006) Nadph oxidases in cardiovascular health and disease. Antioxidants & Redox Signaling 8:691–728CrossRef
23.
Zurück zum Zitat Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG (2007) Role of the t cell in the genesis of angiotensin ii induced hypertension and vascular dysfunction. J Exp Med 204:2449–2460PubMedPubMedCentralCrossRef Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG (2007) Role of the t cell in the genesis of angiotensin ii induced hypertension and vascular dysfunction. J Exp Med 204:2449–2460PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat AbdAlla S, Lother H, Langer A, el Faramawy Y, Quitterer U (2004) Factor xiiia transglutaminase crosslinks at1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 119:343–354PubMedCrossRef AbdAlla S, Lother H, Langer A, el Faramawy Y, Quitterer U (2004) Factor xiiia transglutaminase crosslinks at1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 119:343–354PubMedCrossRef
25.
Zurück zum Zitat Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet MJ (2009) Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325:612–616PubMedPubMedCentralCrossRef Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet MJ (2009) Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325:612–616PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979PubMedCrossRef Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979PubMedCrossRef
27.
Zurück zum Zitat Murphy K, Travers P, Walport M (2008) Janeway’s immunobiology. Garland Science, Taylor and Francis Group, LLC, New York Murphy K, Travers P, Walport M (2008) Janeway’s immunobiology. Garland Science, Taylor and Francis Group, LLC, New York
28.
Zurück zum Zitat Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, Group CT. (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131PubMedCrossRef Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, Group CT. (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131PubMedCrossRef
29.
Zurück zum Zitat von Vietinghoff S, Ley K (2010) Interleukin 17 in vascular inflammation. Cytokine Growth Factor Rev 21:463–469CrossRef von Vietinghoff S, Ley K (2010) Interleukin 17 in vascular inflammation. Cytokine Growth Factor Rev 21:463–469CrossRef
30.
Zurück zum Zitat Ji Q, Cheng G, Ma N, Huang Y, Lin Y, Zhou Q, Que B, Dong J, Zhou Y, Nie S (2017) Circulating th1, th2, and th17 levels in hypertensive patients. Dis Markers 2017:7146290PubMedPubMedCentralCrossRef Ji Q, Cheng G, Ma N, Huang Y, Lin Y, Zhou Q, Que B, Dong J, Zhou Y, Nie S (2017) Circulating th1, th2, and th17 levels in hypertensive patients. Dis Markers 2017:7146290PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG (2010) Interleukin 17 promotes angiotensin ii-induced hypertension and vascular dysfunction. Hypertension 55:500–507CrossRefPubMed Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG (2010) Interleukin 17 promotes angiotensin ii-induced hypertension and vascular dysfunction. Hypertension 55:500–507CrossRefPubMed
32.
Zurück zum Zitat Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O, Esposito B, Perez N, Yasukawa H, Van Snick J, Yoshimura A, Tedgui A, Mallat Z (2009) Loss of socs3 expression in t cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 206:2067–2077PubMedPubMedCentralCrossRef Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O, Esposito B, Perez N, Yasukawa H, Van Snick J, Yoshimura A, Tedgui A, Mallat Z (2009) Loss of socs3 expression in t cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 206:2067–2077PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Madhur MS, Funt SA, Li L, Vinh A, Chen W, Lob HE, Iwakura Y, Blinder Y, Rahman A, Quyyumi AA, Harrison DG (2011) Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e‑deficient mice. Arterioscler Thromb Vasc Biol 31:1565–1572PubMedPubMedCentralCrossRef Madhur MS, Funt SA, Li L, Vinh A, Chen W, Lob HE, Iwakura Y, Blinder Y, Rahman A, Quyyumi AA, Harrison DG (2011) Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e‑deficient mice. Arterioscler Thromb Vasc Biol 31:1565–1572PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Simon T, Taleb S, Danchin N, Laurans L, Rousseau B, Cattan S, Montely JM, Dubourg O, Tedgui A, Kotti S, Mallat Z (2013) Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J 34:570–577PubMedCrossRef Simon T, Taleb S, Danchin N, Laurans L, Rousseau B, Cattan S, Montely JM, Dubourg O, Tedgui A, Kotti S, Mallat Z (2013) Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J 34:570–577PubMedCrossRef
35.
Zurück zum Zitat Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, Baer A, Antigua J, Van Voorhees AS, Torigian DA, Alavi A, Gelfand JM (2011) Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18 f]-fluorodeoxyglucose positron emission tomography-computed tomography (fdg-pet/ct): a pilot study. Arch Dermatol 147:1031–1039PubMedPubMedCentralCrossRef Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, Baer A, Antigua J, Van Voorhees AS, Torigian DA, Alavi A, Gelfand JM (2011) Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18 f]-fluorodeoxyglucose positron emission tomography-computed tomography (fdg-pet/ct): a pilot study. Arch Dermatol 147:1031–1039PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Arican O, Aral M, Sasmaz S, Ciragil P (2005) Serum levels of tnf-alpha, ifn-gamma, il‑6, il‑8, il-12, il-17, and il-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005:273–279PubMedPubMedCentralCrossRef Arican O, Aral M, Sasmaz S, Ciragil P (2005) Serum levels of tnf-alpha, ifn-gamma, il‑6, il‑8, il-12, il-17, and il-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005:273–279PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Croxford AL, Karbach S, Kurschus FC, Wortge S, Nikolaev A, Yogev N, Klebow S, Schuler R, Reissig S, Piotrowski C, Brylla E, Bechmann I, Scheller J, Rose-John S, Wunderlich FT, Munzel T, von Stebut E, Waisman A (2014) Il‑6 regulates neutrophil microabscess formation in il-17a-driven psoriasiform lesions. J Invest Dermatol 134:728–735PubMedCrossRef Croxford AL, Karbach S, Kurschus FC, Wortge S, Nikolaev A, Yogev N, Klebow S, Schuler R, Reissig S, Piotrowski C, Brylla E, Bechmann I, Scheller J, Rose-John S, Wunderlich FT, Munzel T, von Stebut E, Waisman A (2014) Il‑6 regulates neutrophil microabscess formation in il-17a-driven psoriasiform lesions. J Invest Dermatol 134:728–735PubMedCrossRef
38.
Zurück zum Zitat Karbach S, Croxford AL, Oelze M, Schuler R, Minwegen D, Wegner J, Koukes L, Yogev N, Nikolaev A, Reissig S, Ullmann A, Knorr M, Waldner M, Neurath MF, Li H, Wu Z, Brochhausen C, Scheller J, Rose-John S, Piotrowski C, Bechmann I, Radsak M, Wild P, Daiber A, von Stebut E, Wenzel P, Waisman A, Munzel T (2014) Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol 34:2658–2668PubMedCrossRef Karbach S, Croxford AL, Oelze M, Schuler R, Minwegen D, Wegner J, Koukes L, Yogev N, Nikolaev A, Reissig S, Ullmann A, Knorr M, Waldner M, Neurath MF, Li H, Wu Z, Brochhausen C, Scheller J, Rose-John S, Piotrowski C, Bechmann I, Radsak M, Wild P, Daiber A, von Stebut E, Wenzel P, Waisman A, Munzel T (2014) Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol 34:2658–2668PubMedCrossRef
39.
Zurück zum Zitat Boehncke WH, Boehncke S, Tobin AM, Kirby B (2011) The “psoriatic march”: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 20:303–307PubMedCrossRef Boehncke WH, Boehncke S, Tobin AM, Kirby B (2011) The “psoriatic march”: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 20:303–307PubMedCrossRef
40.
Zurück zum Zitat Joshi AA, Lerman JB, Dey AK, Sajja AP, Belur AD, Elnabawi YA, Rodante JA, Aberra TM, Chung J, Salahuddin T, Natarajan B, Dave J, Goyal A, Groenendyk JW, Rivers JP, Baumer Y, Teague HL, Playford MP, Bluemke DA, Ahlman MA, Chen MY, Gelfand JM, Mehta NN (2018) Association between aortic vascular inflammation and coronary artery plaque characteristics in psoriasis. jama Cardiol 3:949–956PubMedPubMedCentralCrossRef Joshi AA, Lerman JB, Dey AK, Sajja AP, Belur AD, Elnabawi YA, Rodante JA, Aberra TM, Chung J, Salahuddin T, Natarajan B, Dave J, Goyal A, Groenendyk JW, Rivers JP, Baumer Y, Teague HL, Playford MP, Bluemke DA, Ahlman MA, Chen MY, Gelfand JM, Mehta NN (2018) Association between aortic vascular inflammation and coronary artery plaque characteristics in psoriasis. jama Cardiol 3:949–956PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Elnabawi YA, Dey AK, Goyal A, Groenendyk JW, Chung JH, Belur AD, Rodante J, Harrington CL, Teague HL, Baumer Y, Keel A, Playford MP, Sandfort V, Chen MY, Lockshin B, Gelfand JM, Bluemke DA, Mehta NN (2019) Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: Results from a prospective observational study. Cardiovasc Res 115:721–728PubMedPubMedCentralCrossRef Elnabawi YA, Dey AK, Goyal A, Groenendyk JW, Chung JH, Belur AD, Rodante J, Harrington CL, Teague HL, Baumer Y, Keel A, Playford MP, Sandfort V, Chen MY, Lockshin B, Gelfand JM, Bluemke DA, Mehta NN (2019) Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: Results from a prospective observational study. Cardiovasc Res 115:721–728PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Boehncke S, Salgo R, Garbaraviciene J, Beschmann H, Hardt K, Diehl S, Fichtlscherer S, Thaci D, Boehncke WH (2011) Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: Results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 25:1187–1193PubMedCrossRef Boehncke S, Salgo R, Garbaraviciene J, Beschmann H, Hardt K, Diehl S, Fichtlscherer S, Thaci D, Boehncke WH (2011) Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: Results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 25:1187–1193PubMedCrossRef
43.
Zurück zum Zitat Schuler R, Brand A, Klebow S, Wild J, Veras FP, Ullmann E, Roohani S, Kolbinger F, Kossmann S, Wohn C, Daiber A, Munzel T, Wenzel P, Waisman A, Clausen BE, Karbach S (2019) Antagonization of il-17a attenuates skin inflammation and vascular dysfunction in mouse models of psoriasis. J Invest Dermatol 139:638–647PubMedCrossRef Schuler R, Brand A, Klebow S, Wild J, Veras FP, Ullmann E, Roohani S, Kolbinger F, Kossmann S, Wohn C, Daiber A, Munzel T, Wenzel P, Waisman A, Clausen BE, Karbach S (2019) Antagonization of il-17a attenuates skin inflammation and vascular dysfunction in mouse models of psoriasis. J Invest Dermatol 139:638–647PubMedCrossRef
44.
Zurück zum Zitat Wu JJ, Poon KY, Channual JC, Shen AY (2012) Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 148:1244–1250PubMedCrossRef Wu JJ, Poon KY, Channual JC, Shen AY (2012) Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 148:1244–1250PubMedCrossRef
45.
Zurück zum Zitat von Stebut E, Reich K, Thaci D, Koenig W, Pinter A, Korber A, Rassaf T, Waisman A, Mani V, Yates D, Frueh J, Sieder C, Melzer N, Mehta NN, Gori T (2019) Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol 139:1054–1062CrossRef von Stebut E, Reich K, Thaci D, Koenig W, Pinter A, Korber A, Rassaf T, Waisman A, Mani V, Yates D, Frueh J, Sieder C, Melzer N, Mehta NN, Gori T (2019) Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol 139:1054–1062CrossRef
46.
Zurück zum Zitat Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernan MA, Ridker PM, Mozaffarian D (2011) Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108:1362–1370PubMedPubMedCentralCrossRef Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernan MA, Ridker PM, Mozaffarian D (2011) Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108:1362–1370PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM (2017) Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 176:890–901PubMedPubMedCentralCrossRef Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM (2017) Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 176:890–901PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: Expert opinion of the canadian dermatology-rheumatology comorbidity initiative. J Rheumatol 42:1767–1780PubMedCrossRef Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: Expert opinion of the canadian dermatology-rheumatology comorbidity initiative. J Rheumatol 42:1767–1780PubMedCrossRef
49.
Zurück zum Zitat Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG, National Psoriasis Foundation (2008) National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 58:1031–1042PubMedPubMedCentralCrossRef Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG, National Psoriasis Foundation (2008) National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 58:1031–1042PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Schuler R, Efentakis P, Wild J, Lagrange J, Garlapati V, Molitor M, Kossmann S, Oelze M, Stamm P, Li H, Schafer K, Munzel T, Daiber A, Waisman A, Wenzel P, Karbach SH (2019) T cell-derived il-17a induces vascular dysfunction via perivascular fibrosis formation and dysregulation of ⋅NO/cGMP signaling. Oxid Med Cell Longev 2019:6721531PubMedPubMedCentralCrossRef Schuler R, Efentakis P, Wild J, Lagrange J, Garlapati V, Molitor M, Kossmann S, Oelze M, Stamm P, Li H, Schafer K, Munzel T, Daiber A, Waisman A, Wenzel P, Karbach SH (2019) T cell-derived il-17a induces vascular dysfunction via perivascular fibrosis formation and dysregulation of ⋅NO/cGMP signaling. Oxid Med Cell Longev 2019:6721531PubMedPubMedCentralCrossRef
Metadaten
Titel
Von der Haut zum Gefäßsystem – Psoriasis und das kardiovaskuläre Risiko
verfasst von
Dr. med. Johannes Wild
Joanna Wegner
Dr. med. Susanne Karbach
Publikationsdatum
23.01.2020
Verlag
Springer Medizin
Erschienen in
Die Kardiologie / Ausgabe 3/2020
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI
https://doi.org/10.1007/s12181-019-00373-0

Weitere Artikel der Ausgabe 3/2020

Die Kardiologie 3/2020 Zur Ausgabe

Passend zum Thema

ANZEIGE

Die entscheidende Rolle des Mikrobioms bei atopischer Dermatitis

Bei atopischer Dermatitis besteht eine direkte Korrelation des Schweregrad der Erkrankung und einer verminderten Diversität des Mikrobioms. Studiendaten zeigen, dass durch eine Behandlung mit Emollienzien plus, die Besiedelung mit Staphylokokken reduziert und das Mikrobiom stabilisiert werden kann.

ANZEIGE

Welche Bedeutung hat das Mikrobiom bei Wundheilung und AD?

Warum hat das Mikrobiom der Haut in den letzten Jahren in der Wissenschaft an enormer Bedeutung gewonnen? Welche Möglichkeiten ergeben sich dadurch für die Behandlung bei Hautkrankheiten wie atopischer Dermatitis und der Wundheilung? Dies erläutert Prof. Thomas Luger im Interview.

ANZEIGE

Neueste Erkenntnisse zum Hautmikrobiom: vier Experten im Gespräch

Content Hub

Die Experten Prof. Luger (Münster), Prof. Zuberbier (Berlin), Prof. Thaçi (Lübeck) und PD Dr. Jansen (Essen) erörtern im von La Roche Posay unterstützen Expertenworkshop die Bedeutung des Mikrobioms für verschiedene Hautkrankheiten wie atopische Dermatitis, Akne oder Rosazea.

La Roche Posay